Equities Analysts Set Expectations for HURA Q2 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Research analysts at Zacks Research issued their Q2 2026 EPS estimates for shares of TuHURA Biosciences in a research report issued to clients and investors on Tuesday, May 26th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.21) for the quarter. The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.45) per share. Zacks Research also issued estimates for TuHURA Biosciences’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.16 EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.52) EPS.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Citigroup began coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set an “outperform” rating for the company. Finally, Citizens Jmp began coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, TuHURA Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Down 2.9%

HURA stock opened at $2.38 on Thursday. The firm has a 50 day moving average of $2.25 and a 200 day moving average of $1.61. The stock has a market capitalization of $151.56 million, a PE ratio of -3.90 and a beta of -0.01. TuHURA Biosciences has a 52 week low of $0.41 and a 52 week high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last released its earnings results on Friday, May 15th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Trading of TuHURA Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HURA. Virtu Financial LLC acquired a new stake in TuHURA Biosciences during the third quarter valued at $26,000. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences during the second quarter valued at $27,000. Wells Fargo & Company MN grew its position in TuHURA Biosciences by 109.0% during the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after buying an additional 19,931 shares during the period. Invesco Ltd. acquired a new stake in TuHURA Biosciences during the second quarter valued at $30,000. Finally, Goldman Sachs Group Inc. acquired a new stake in TuHURA Biosciences during the fourth quarter valued at $30,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.